AF Symposium 25: LAAC Vs Oral Anticoagulation After Catheter Ablation

5 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Left atrial appendage (LAA) closure using the WATCHMAN FLX device (Boston Scientific) showed lower risk of bleeding and non-inferiority in efficacy endpoints to oral anticoagulation in patients who have received or are planning to receive AF ablation.

Dr Walid Saliba (Cleveland Clinic, OH, US) joins us onsite at AF Symposium 25 to discuss the findings from the concomitant and sequential cohorts of the OPTION trial comparing LAA closure with the WATCHMAN FLX device verses oral anticoagulation. The primary safety endpoint was non–procedure-related major bleeding or clinically relevant nonmajor bleeding. The primary efficacy endpoint was a composite of all-cause mortality, stroke, or systemic embolism.

Findings showed that in the concomitant and sequential cohorts, the three-year efficacy outcomes were similar in both treatment arms, whilst the safety outcomes revealed that LAAC with the WATCHMAN FLX device reduced non-procedural bleeding outcomes compared to oral anticoagulation.

Interview Questions:
1. Could you give a brief summary of the trial and the reasoning behind it?
2. What was the patient population and study design?
3. What are the key findings?
4. How should these findings impact patient treatment?

Recorded on-site at AF Symposium in Boston, 2025.

Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: https://www.facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO
Category
Cardiology
Be the first to comment

Up Next